Cargando…
Class A and C GPCR Dimers in Neurodegenerative Diseases
Neurodegenerative diseases affect over 30 million people worldwide with an ascending trend. Most individuals suffering from these irreversible brain damages belong to the elderly population, with onset between 50 and 60 years. Although the pathophysiology of such diseases is partially known, it rema...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886835/ https://www.ncbi.nlm.nih.gov/pubmed/35339177 http://dx.doi.org/10.2174/1570159X20666220327221830 |
_version_ | 1784880205326712832 |
---|---|
author | Caniceiro, Ana B. Bueschbell, Beatriz Schiedel, Anke C. Moreira, Irina S. |
author_facet | Caniceiro, Ana B. Bueschbell, Beatriz Schiedel, Anke C. Moreira, Irina S. |
author_sort | Caniceiro, Ana B. |
collection | PubMed |
description | Neurodegenerative diseases affect over 30 million people worldwide with an ascending trend. Most individuals suffering from these irreversible brain damages belong to the elderly population, with onset between 50 and 60 years. Although the pathophysiology of such diseases is partially known, it remains unclear upon which point a disease turns degenerative. Moreover, current therapeutics can treat some of the symptoms but often have severe side effects and become less effective in long-term treatment. For many neurodegenerative diseases, the involvement of G protein-coupled receptors (GPCRs), which are key players of neuronal transmission and plasticity, has become clearer and holds great promise in elucidating their biological mechanism. With this review, we introduce and summarize class A and class C GPCRs, known to form heterodimers or oligomers to increase their signalling repertoire. Additionally, the examples discussed here were shown to display relevant alterations in brain signalling and had already been associated with the pathophysiology of certain neurodegenerative diseases. Lastly, we classified the heterodimers into two categories of crosstalk, positive or negative, for which there is known evidence. |
format | Online Article Text |
id | pubmed-9886835 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Bentham Science Publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-98868352023-04-27 Class A and C GPCR Dimers in Neurodegenerative Diseases Caniceiro, Ana B. Bueschbell, Beatriz Schiedel, Anke C. Moreira, Irina S. Curr Neuropharmacol Neurology Neurodegenerative diseases affect over 30 million people worldwide with an ascending trend. Most individuals suffering from these irreversible brain damages belong to the elderly population, with onset between 50 and 60 years. Although the pathophysiology of such diseases is partially known, it remains unclear upon which point a disease turns degenerative. Moreover, current therapeutics can treat some of the symptoms but often have severe side effects and become less effective in long-term treatment. For many neurodegenerative diseases, the involvement of G protein-coupled receptors (GPCRs), which are key players of neuronal transmission and plasticity, has become clearer and holds great promise in elucidating their biological mechanism. With this review, we introduce and summarize class A and class C GPCRs, known to form heterodimers or oligomers to increase their signalling repertoire. Additionally, the examples discussed here were shown to display relevant alterations in brain signalling and had already been associated with the pathophysiology of certain neurodegenerative diseases. Lastly, we classified the heterodimers into two categories of crosstalk, positive or negative, for which there is known evidence. Bentham Science Publishers 2022-10-27 2022-10-27 /pmc/articles/PMC9886835/ /pubmed/35339177 http://dx.doi.org/10.2174/1570159X20666220327221830 Text en © 2022 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. |
spellingShingle | Neurology Caniceiro, Ana B. Bueschbell, Beatriz Schiedel, Anke C. Moreira, Irina S. Class A and C GPCR Dimers in Neurodegenerative Diseases |
title | Class A and C GPCR Dimers in Neurodegenerative Diseases |
title_full | Class A and C GPCR Dimers in Neurodegenerative Diseases |
title_fullStr | Class A and C GPCR Dimers in Neurodegenerative Diseases |
title_full_unstemmed | Class A and C GPCR Dimers in Neurodegenerative Diseases |
title_short | Class A and C GPCR Dimers in Neurodegenerative Diseases |
title_sort | class a and c gpcr dimers in neurodegenerative diseases |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886835/ https://www.ncbi.nlm.nih.gov/pubmed/35339177 http://dx.doi.org/10.2174/1570159X20666220327221830 |
work_keys_str_mv | AT caniceiroanab classaandcgpcrdimersinneurodegenerativediseases AT bueschbellbeatriz classaandcgpcrdimersinneurodegenerativediseases AT schiedelankec classaandcgpcrdimersinneurodegenerativediseases AT moreirairinas classaandcgpcrdimersinneurodegenerativediseases |